MX343227B - Anticuerpos anti-erbb3. - Google Patents

Anticuerpos anti-erbb3.

Info

Publication number
MX343227B
MX343227B MX2012011718A MX2012011718A MX343227B MX 343227 B MX343227 B MX 343227B MX 2012011718 A MX2012011718 A MX 2012011718A MX 2012011718 A MX2012011718 A MX 2012011718A MX 343227 B MX343227 B MX 343227B
Authority
MX
Mexico
Prior art keywords
her3
antibodies
erbb3 antibodies
activation
erbb3
Prior art date
Application number
MX2012011718A
Other languages
English (en)
Other versions
MX2012011718A (es
Inventor
Fang Wang
Lyne Breault
Jeno Gyuris
William M Winston Jr
Sylvie Vincent
Solly Weiler
Kristan Meetze
Steve Botega
Ting Chen
Michael Deprima
Christina Fleet
Steven Tyler
Jin-Kyeung Woo
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Publication of MX2012011718A publication Critical patent/MX2012011718A/es
Publication of MX343227B publication Critical patent/MX343227B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos monoclonales que se unen al miembro relacionado con el receptor del factor de crecimiento epidérmico ErbB3/HER3 e inhiben la activación del mismo. Los anticuerpos pueden ser empleados para tratar enfermedades y trastornos proliferativos celulares, incluyendo ciertas formas de cáncer, asociados con la activación de ErbB3/HER3.
MX2012011718A 2010-04-09 2011-04-08 Anticuerpos anti-erbb3. MX343227B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32271210P 2010-04-09 2010-04-09
PCT/US2011/031829 WO2011136911A2 (en) 2010-04-09 2011-04-08 Anti-erbb3 antibodies

Publications (2)

Publication Number Publication Date
MX2012011718A MX2012011718A (es) 2012-12-17
MX343227B true MX343227B (es) 2016-10-28

Family

ID=44120965

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011718A MX343227B (es) 2010-04-09 2011-04-08 Anticuerpos anti-erbb3.

Country Status (18)

Country Link
US (6) US8481687B2 (es)
EP (1) EP2566895B1 (es)
JP (1) JP5906233B2 (es)
KR (1) KR101764453B1 (es)
CN (2) CN102884085B (es)
AR (1) AR080873A1 (es)
AU (1) AU2011245636B2 (es)
BR (1) BR112012025730B1 (es)
CA (1) CA2795799C (es)
ES (1) ES2566602T3 (es)
IL (1) IL222272B (es)
MX (1) MX343227B (es)
NZ (1) NZ603271A (es)
PH (1) PH12012502022B1 (es)
RU (1) RU2568051C2 (es)
SG (1) SG184452A1 (es)
WO (1) WO2011136911A2 (es)
ZA (1) ZA201208290B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2638823A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
EP2132312B1 (en) 2007-03-27 2016-01-27 Sea Lane Biotechnologies,llc. Constructs and libraries comprising antibody surrogate light chain sequences
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
CA2782571C (en) 2009-12-22 2018-01-23 Roche Glycart Ag Anti-her3 antibodies and uses thereof
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
PL2606070T3 (pl) 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
EP3156421B1 (en) 2010-11-01 2018-06-06 Symphogen A/S Pan-her antibody composition
ITRM20100577A1 (it) 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
AU2012229147B2 (en) 2011-03-11 2015-12-24 Merrimack Pharmaceuticals, Inc. Use of inhibitors of EGFR-family receptors in the treatment of hormone refractory breast cancers
US20150231238A1 (en) 2011-03-15 2015-08-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
KR20140138353A (ko) 2011-04-19 2014-12-03 메리맥 파마슈티컬즈, 인크. 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
EP2736928B1 (en) * 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
CA2849508C (en) * 2011-09-30 2020-12-22 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
AU2012318541B2 (en) * 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
AU2012340766B2 (en) * 2011-11-23 2018-05-10 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US20130273029A1 (en) * 2011-12-05 2013-10-17 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
MX2014006731A (es) * 2011-12-05 2015-06-04 Novartis Ag Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3) dirigidos al dominio iii y al dominio iv del her3.
AU2012349735B2 (en) * 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
EP2793940B1 (en) 2011-12-22 2018-11-14 i2 Pharmaceuticals, Inc. Surrogate binding proteins
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
MX2015011712A (es) 2013-03-06 2016-04-04 Merrimack Pharmaceuticals Inc Anticerpos biespecificos fc en fila anti-c-met.
EP2821071A1 (en) 2013-07-04 2015-01-07 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for breast cancer treatment
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2015138411A1 (en) * 2014-03-10 2015-09-17 The Brigham And Women's Hospital, Inc. Anti-fibulin-3 antibodies and uses thereof
KR20170003912A (ko) 2014-03-19 2017-01-10 매카이 메디컬 파운데이션 더 프레즈비티리언 처치 인 타이완 매카이 메모리얼 호스피탈 면역원성 당펩타이드에 대한 항체, 이를 포함하는 조성물 및 이의 용도
EP3662928A1 (en) 2014-04-10 2020-06-10 OBI Pharma Inc. Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
US10526416B2 (en) 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
JP2017534574A (ja) 2014-09-08 2017-11-24 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法
KR102390359B1 (ko) * 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
CN104861068B (zh) * 2015-01-23 2020-11-17 中国人民解放军军事科学院军事医学研究院 一种全人源抗her3抗体及其治疗相关疾病的用途
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN108472362B (zh) 2015-10-07 2022-03-29 台湾浩鼎生技股份有限公司 新颖糖类抗体、医药组成物及其用途
WO2017087547A1 (en) * 2015-11-17 2017-05-26 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
CA3004743A1 (en) * 2015-11-24 2017-06-01 Cellerant Therapeutics, Inc. Humanized anti-cll-1 antibodies
KR101746152B1 (ko) * 2015-12-07 2017-06-13 주식회사 이수앱지스 ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
JP2019508428A (ja) 2016-03-15 2019-03-28 メリマック ファーマシューティカルズ インコーポレーティッド 抗ｅｒｂｂ３抗体を含む組み合わせ療法を用いて、ｅｒ＋、ｈｅｒ２−、ｈｒｇ＋乳癌を治療するための方法
AU2017282892B2 (en) 2016-06-23 2023-10-26 Jiangsu Hengrui Medicine Co., Ltd. LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
CN106692969B (zh) * 2016-12-08 2021-08-10 北海康成（北京）医药科技有限公司 抗erbb3抗体及其用途
JP2020511950A (ja) 2016-12-22 2020-04-23 アイカーン スクール オブ メディスン アット マウント シナイ 抗ｌｉｌｒｂ３抗体およびその使用の方法
BR112019015915A2 (pt) 2017-02-28 2020-04-07 Daiichi Sankyo Co Ltd método para o tratamento de câncer de pulmão de células não pequenas resistentes a egfr-tki através da administração do conjugado de anticorpo anti-her3-fármaco
JOP20180021A1 (ar) * 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
EP3600421A4 (en) * 2017-03-23 2021-01-06 The Trustees of The University of Pennsylvania ANTI-C5A ANTIBODIES AND USES OF THEM
CN113621706B (zh) * 2017-06-22 2024-05-10 北海康成（北京）医药科技有限公司 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
US11161897B2 (en) * 2017-07-17 2021-11-02 Janssen Biotech, Inc. Antigen binding regions against fibronectin type III domains and methods of using the same
US11021540B2 (en) * 2017-09-07 2021-06-01 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
WO2019076277A1 (zh) * 2017-10-17 2019-04-25 江苏恒瑞医药股份有限公司 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
AU2019232631A1 (en) 2018-03-05 2020-09-24 Janssen Pharmaceutica Nv Anti-PHF-tau antibodies and uses thereof
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
EP3773658A4 (en) 2018-04-06 2022-04-27 Dana-Farber Cancer Institute, Inc. KIR3DL3 AS HLA2 RECEPTOR, ANTI-HHLA2 ANTIBODY AND ITS USES
WO2020059772A1 (ja) 2018-09-20 2020-03-26 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
US20220106398A1 (en) * 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
WO2020214957A1 (en) * 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
CN112898414B (zh) * 2019-12-04 2024-05-10 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
US20230075244A1 (en) * 2020-02-20 2023-03-09 The Feinstein Institutes For Medical Research Agonist antibodies against endoglin and uses thereof
MX2022011335A (es) * 2020-03-18 2022-10-07 Kindred Biosciences Inc Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
WO2022144025A1 (zh) * 2021-01-04 2022-07-07 上海翰森生物医药科技有限公司 一种抗erbb3受体的抗体或其抗原结合片段及其医药用途
WO2023147470A2 (en) 2022-01-28 2023-08-03 Georgiamune Inc. Antibodies to programmed cell death protein 1 that are pd-1 agonists
CN114940714B (zh) * 2022-05-20 2023-06-16 湖南师范大学 肝癌标志物soat1单克隆抗体制备及其应用
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CN115109161B (zh) * 2022-06-28 2023-08-11 广东赛尔生物科技有限公司 含有间充质干细胞的减肥药物组合物
WO2024138019A1 (en) * 2022-12-23 2024-06-27 Actinium Pharmaceuticals, Inc. Her3 radioimmunotherapy for the treatment of solid cancers
KR20260020406A (ko) 2023-06-02 2026-02-11 다이이찌 산쿄 가부시키가이샤 항 her3 항체-약물 콘주게이트와 rasg12c 저해제의 조합
CN118005795B (zh) * 2024-04-09 2024-06-28 天津旷博同生生物技术有限公司 一种抗人cd64抗体及应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL126303A (en) * 1996-03-27 2002-05-23 Genentech Inc ErbB3 ANTIBODIES
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
US20070009972A1 (en) 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
PL2129396T3 (pl) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
AU2010242914B2 (en) 2009-04-29 2014-11-13 Trellis Bioscience, Llc Improved antibodies immunoreactive with heregulin-coupled HER3
SG178509A1 (en) 2009-08-21 2012-04-27 Merrimack Pharmaceuticals Inc Antibodies against the ectodomain of erbb3 and uses thereof
CA2775573A1 (en) 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
CA2782571C (en) 2009-12-22 2018-01-23 Roche Glycart Ag Anti-her3 antibodies and uses thereof
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
WO2012052230A1 (en) * 2010-10-18 2012-04-26 Mediapharma S.R.L. Erbb3 binding antibody
AU2012318541B2 (en) * 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies

Also Published As

Publication number Publication date
CN102884085B (zh) 2016-08-03
US20160264679A1 (en) 2016-09-15
US20180030149A1 (en) 2018-02-01
CN105968206B (zh) 2020-01-17
US9228021B2 (en) 2016-01-05
CA2795799C (en) 2018-09-25
SG184452A1 (en) 2012-11-29
US12486332B2 (en) 2025-12-02
NZ603271A (en) 2014-05-30
PH12012502022A1 (en) 2013-01-21
CA2795799A1 (en) 2011-11-03
BR112012025730B1 (pt) 2020-12-08
US8481687B2 (en) 2013-07-09
WO2011136911A2 (en) 2011-11-03
PH12012502022B1 (en) 2019-03-08
US10494441B2 (en) 2019-12-03
BR112012025730A8 (pt) 2017-05-23
US9598498B2 (en) 2017-03-21
KR101764453B1 (ko) 2017-08-02
RU2568051C2 (ru) 2015-11-10
CN102884085A (zh) 2013-01-16
AU2011245636B2 (en) 2016-12-22
ES2566602T3 (es) 2016-04-14
BR112012025730A2 (pt) 2017-01-10
ZA201208290B (en) 2013-07-31
IL222272A0 (en) 2012-12-31
AR080873A1 (es) 2012-05-16
US20130330772A1 (en) 2013-12-12
EP2566895B1 (en) 2015-12-30
JP2013523166A (ja) 2013-06-17
RU2012147591A (ru) 2014-05-20
US20230365710A1 (en) 2023-11-16
KR20130043106A (ko) 2013-04-29
MX2012011718A (es) 2012-12-17
IL222272B (en) 2018-04-30
WO2011136911A3 (en) 2012-03-08
CN105968206A (zh) 2016-09-28
AU2011245636A2 (en) 2012-11-29
HK1178184A1 (zh) 2013-09-06
JP5906233B2 (ja) 2016-04-20
EP2566895A2 (en) 2013-03-13
US20110256154A1 (en) 2011-10-20
US11680108B2 (en) 2023-06-20
US20200299406A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
MX343227B (es) Anticuerpos anti-erbb3.
PH12012502215A1 (en) Anti-fgfr2 antibodies
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
PH12014502419A1 (en) Specific binding proteins and uses thereof
EA201390575A1 (ru) Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
PH12014500483A1 (en) Anti-erbb3 antibodies and uses thereof
EP4530630A3 (en) Monoclonal antibodies and methods of use
PH12014502641B1 (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
EA201591198A1 (ru) Антитела к gdf15
MX375439B (es) Moleculas de union cd37 y sus inmunoconjugados.
WO2012019024A3 (en) Her3-binding molecules and immunoconjugates thereof
MX2022001086A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
MX348637B (es) Anticuerpos y composiciones anti-her3.
MX359794B (es) Anticuerpos anti-hepcidina y usos de los mismos.
EA201300996A1 (ru) Использование ингибиторов рецепторов семейства egfr в лечении гормонорезистентного рака молочной железы
WO2010002862A3 (en) Fibroblast growth factor receptor 3 (fgfr3) binding proteins
WO2011156617A3 (en) Anti-egfr antibodies
MX2015008313A (es) Terapia de combinacion de anticuerpos anti-her3.
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
PH12015500751A1 (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
WO2014172653A3 (en) Anti-notch1 antibodies
NZ729725A (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration